GVK Biosciences forms
Clinical Research Alliance with Excel PharmaStudies, to Conduct Trials in
India and China
BIO – Excel have Decided to Form an Alliance to
Build on the Strengths of Each Company and Offer
Clients with Services that Span India and China
GVK Biosciences (GVK BIO), Asia’s leading integrated research services
provider and Excel PharmaStudies (Excel), a leading Chinese Clinical
Research Organization announced a strategic alliance to conduct Clinical
Trials in Asia.
The alliance provides clinical trial sponsors access to the scientific
skills, talent pool, flexible resourcing, and cost-effectiveness of both
India and China. India has sponsor friendly regulations and strength in
Phase II/III clinical trials; China has strengths in its large market,
Phase III and post marketing Phase IV studies; Through the GVK BIO-Excel
alliance sponsors will be able to conduct Phase II-IV trials using India
and China as required with speed and efficiency.
Under the terms of the arrangement, GVK BIO and Excel will help sponsors
conduct and manage Phase II-IV clinical trials, statistical analysis and
medical writing. Any India trial for Excel will be carried out by the GVK
BIO clinical research team and will be managed by a core project
management team of Excel. Similarly, a GVK BIO China trial will be carried
out by the Excel team and managed by GVK BIO’s project management team.
“This is a first of a kind alliance between an Indian CRO and a Chinese
CRO. The GVK BIO-Excel alliance integrates trial management across India
and China and provides sponsors with a single point of contact”, said
Manni Kantipudi, President GVK BIO.
“It is an important step for Excel, and our clients, to be able to provide
full services in both important countries”, said Dr. William Xiong, CEO
The decision to form such an alliance comes close on heels of GVK
Biosciences increased focus on Clinical Development. GVK BIO had recently
strengthened its team by hiring Dr. Shoibal Mukherjee, ex-Pfizer as its
Clinical Development Head. GVK BIO also added new services in
pharmacovigilance and medical writing operating from its Clinical Research
Facility in Gurgaon, India.
Reachout's News Bureau